Company intelligence / Profile preview

AdAlta

Bundoora, Victoria, Australiaadalta.com.au ↗

Ownership: Public · 1AD
Employees: ~9
Development stage: Phase 1

Overview

Lead asset AD-214 is in Phase 2 clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. The company has also developed i-CAR-T cell therapies for solid tumors and i-PET imaging for cancer patients.

Therapeutic areas: OtherOphthalmologyOncologyPulmonology
Modalities: Protein therapeuticsi-body platformCell-based therapeutics
Industry: Biotech

Drug pipeline

5 assets

AD-214

4 more assets in the full pipeline.

Request access →

Partnerships

GE Healthcare Technologies Inc (for i-body enabled PET imaging agents)Carina Biotech Pty Ltd (for CAR-T cell therapies)

Beyond the preview

Go deeper on AdAlta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AdAlta.

Explore the full profile